Drug intelligence / Profile preview

SIM0518

Development stage: Preclinical
Lead developer: Nanjing Zaiming Pharmaceutical
Modality: Small Molecules

Overview

SIM0518 is a preclinical-stage small molecule inhibitor of Anaplastic Lymphoma Kinase (ALK) being developed by Nanjing Zaiming Pharmaceutical, a subsidiary of Simcere Pharmaceutical Group. It is designed for the treatment of solid tumors that are driven by ALK signaling, such as those harboring ALK rearrangements or mutations. As a targeted therapy, SIM0518 aims to inhibit the kinase activity of ALK, thereby disrupting downstream pathways involved in cell proliferation and survival. The drug is currently in the preclinical phase of development.

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)

Beyond the preview

Go deeper on SIM0518.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0518.

Explore the full profile